Novartis to Invest $23B in 46,000-Sq-Ft Texas Radioligand Plant
Novartis plans a 46,000 sq ft radioligand therapy manufacturing facility in Denton, Texas, its fifth U.S. site, launching construction in 2026 for 2028 operation as part of its $23 billion U.S. investment. Banco Santander trimmed its Novartis holding by 51.4% in Q3, offloading 32,075 shares to 30,286 shares.
1. New Radioligand Manufacturing Facility in Texas
Novartis announced plans on February 25 to build a 46,000-square-foot radioligand therapy (RLT) manufacturing facility in Denton, Texas. As its fifth U.S. RLT site and first in Texas, the plant is part of a broader $23 billion U.S. investment, with construction slated to begin in 2026 and full operations by 2028, creating advanced manufacturing, bioengineering, quality, and operations roles.
2. Banco Santander Reduces Novartis Stake
During the third quarter, Banco Santander reduced its Novartis shareholding by 51.4%, selling 32,075 shares and retaining 30,286 shares. This significant divestment may reflect shifting institutional strategies and could influence market perception of Novartis as investors reassess large-cap pharmaceutical positions.